39,000 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Bought by Handelsbanken Fonder AB

Handelsbanken Fonder AB bought a new position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 39,000 shares of the company’s stock, valued at approximately $309,000.

Other large investors have also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in Amneal Pharmaceuticals by 149.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock valued at $10,792,000 after purchasing an additional 777,568 shares during the period. Barclays PLC grew its position in Amneal Pharmaceuticals by 134.1% in the 3rd quarter. Barclays PLC now owns 296,384 shares of the company’s stock valued at $2,466,000 after purchasing an additional 169,756 shares during the period. State Street Corp increased its stake in Amneal Pharmaceuticals by 3.8% during the 3rd quarter. State Street Corp now owns 3,514,721 shares of the company’s stock valued at $29,242,000 after purchasing an additional 127,753 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Amneal Pharmaceuticals during the 4th quarter valued at $520,000. Finally, Geode Capital Management LLC increased its holdings in Amneal Pharmaceuticals by 11.1% during the 3rd quarter. Geode Capital Management LLC now owns 3,786,671 shares of the company’s stock worth $31,511,000 after purchasing an additional 378,136 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Price Performance

AMRX opened at $8.76 on Tuesday. The firm has a market capitalization of $2.71 billion, a P/E ratio of -12.88 and a beta of 1.10. Amneal Pharmaceuticals, Inc. has a one year low of $5.18 and a one year high of $9.48. The company has a fifty day moving average price of $8.12 and a 200-day moving average price of $8.33.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). The business had revenue of $730.52 million during the quarter, compared to the consensus estimate of $708.21 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. During the same quarter in the prior year, the company earned $0.14 earnings per share. On average, analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. StockNews.com lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, December 19th. Barclays raised their price objective on shares of Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a report on Monday. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $9.00 to $12.00 in a research note on Monday, February 24th. Finally, Piper Sandler raised their target price on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $10.80.

Insider Activity at Amneal Pharmaceuticals

In other news, Director Gautam Patel sold 17,410 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $8.01, for a total value of $139,454.10. Following the transaction, the director now owns 2,031,476 shares of the company’s stock, valued at $16,272,122.76. This represents a 0.85 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders have sold 160,000 shares of company stock valued at $1,292,000 over the last three months. 26.56% of the stock is owned by corporate insiders.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.